Max-delbrück-centrum Für Molekulare Medizin in Der

Helmholtz-gemeinschaft; Charité—universitätsmedizin Berlin

Charité – Universitätsmedizin Berlin

Max-delbruck-centrum Fur Molekulare Medizin in Der Helmholtz-gemeinschaft

Simone Rhein

Thomas Blankenstein

Antonio Pezzutto

The present invention is directed to the field of immunotherapy, in particular, adoptive T cell therapy or T cell receptor (TCR) gene therapy of cancer, in particular, of B cell lymphoma or B cell leukemia. The invention provides a nucleic acid encoding TCR alpha or beta chain constructs of TCR constructs capable of specifically binding to a peptide of SEQ ID NO: 1, derived from the lineage specific antigen CD22, in the context of HLA-A2 and to subsequently lyse CD22-positive cells. The invention further provides a corresponding protein and host cell. e.g., a CD8+ T cell, pharmaceutical compositions comprising the same, and therapeutic use for treatment of B cell lymphoma or B cell leukemia, such as diffuse large B-cell lymphoma (DLBCL).

Growing community of inventors

Berlin, Germany

Simone Rhein